Cargando…
Ocrelizumab-Induced Severe Colitis
We report a case of severe ocrelizumab (anti-CD20 monoclonal antibody) induced colitis in a 43-year-old woman with multiple sclerosis leading to total colectomy after failing medical therapy. Histology of the colectomy was consistent with medication-induced colitis.
Autores principales: | Lee, Hsing Hwa, Sritharan, Naveen, Bermingham, Daniel, Strey, Gabriela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7737437/ https://www.ncbi.nlm.nih.gov/pubmed/33354373 http://dx.doi.org/10.1155/2020/8858378 |
Ejemplares similares
-
Ocrelizumab-induced inflammatory bowel disease-like illness characterized by esophagitis and colitis
por: Barnes, Alex, et al.
Publicado: (2021) -
Severe late‐onset neutropenia induced by ocrelizumab in a multiple sclerosis patient: A case report
por: Rauniyar, Robin, et al.
Publicado: (2022) -
Ocrelizumab: Prolonged severe acute respiratory syndrome Coronavirus-2 infection: case report
Publicado: (2022) -
Ocrelizumab/rituximab: Various toxicities: 6 case reports
Publicado: (2021) -
Ocrelizumab: Coronavirus disease-2019 : 15 case reports
Publicado: (2022)